Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

NCT02402660 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Stargardt Disease
Stargardt Macular Degeneration
Stargardt Macular Dystrophy
Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Interventions

DRUG: ALK-001
DRUG: Placebo

Sponsor

Alkeus Pharmaceuticals, Inc.